AI Drug Discovery for Pharma and Biotech

Drug discovery

5

papers

On emerging therapies

Overview

Cholestasis-lymphedema syndrome (CLS) is a rare autosomal recessive disorder caused by UNC45A variants, characterized by neonatal cholestasis (often intermittent) and chronic lower-limb lymphedema. Complications include fat malabsorption, vitamin deficiencies, pruritus, and progressive liver disease (25% develop cirrhosis). Management focuses on nutritional support, symptom control, and multidisciplinary care [1][6][11][16].

Population

  • Estimated ~100 cases globally, with a founder effect in southwestern Norway (48 confirmed cases) [6][14].

  • Autosomal recessive inheritance; onset of cholestasis in infancy and lymphedema in early childhood [11][12].

Burden

  • Chronic liver and lymphatic dysfunction lead to recurrent hospitalizations, growth delays, and skeletal abnormalities [4][6].

  • Severe lymphedema correlates with reduced mental health and physical function; 12% of Norwegian patients require liver transplantation [6][11].

  • High healthcare utilization due to lifelong multidisciplinary care needs [6][9].

Therapies

  • Cholestasis: Cholestyramine (pruritus), fat-soluble vitamin supplementation, ursodeoxycholic acid, and liver transplantation for cirrhosis [3][11][16].

  • Lymphedema: Compression garments, decongestive lymphatic therapy, and surgical interventions (e.g., lymphovenous anastomosis) in advanced stages [8][17].

  • Diet: Fat-restricted during cholestatic episodes to reduce malabsorption [13].

Categories: rare circulatory system diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare hepatic diseases, rare skin diseases

Research Papers

5 drug discovery papers about Cholestasis-lymphedema syndrome. Recent publications:

5 drug discovery papers about Cholestasis-lymphedema syndrome. Recent publications:

categories:

Small molecules

proteins
2022-07-01 | Hepatic lymphatic vascular system in health and disease

In recent years, significant advances have been made in the study of lymphatic vessels with the identification of their specific markers and the development of research tools that have accelerated our understanding of their role in tissue homeostasis and disease pathogenesis in many organs. Compared to other organs, the lymphatic system in the liver is understudied despite its obvious importance for hepatic physiology and pathophysiology. In this review, we describe fundamental aspects of the hepatic lymphatic system and its role in a range of liver-related pathological conditions such as portal hypertension, ascites formation, malignant tumours, liver transplantation, congenital liver diseases, non-alcoholic fatty liver disease, and hepatic encephalopathy. The article concludes with a discussion regarding the modulation of lymphangiogenesis as a potential therapeutic strategy for liver diseases.

Open article ↗



proteins
2022-07-01 | Hepatic lymphatic vascular system in health and disease

In recent years, significant advances have been made in the study of lymphatic vessels with the identification of their specific markers and the development of research tools that have accelerated our understanding of their role in tissue homeostasis and disease pathogenesis in many organs. Compared to other organs, the lymphatic system in the liver is understudied despite its obvious importance for hepatic physiology and pathophysiology. In this review, we describe fundamental aspects of the hepatic lymphatic system and its role in a range of liver-related pathological conditions such as portal hypertension, ascites formation, malignant tumours, liver transplantation, congenital liver diseases, non-alcoholic fatty liver disease, and hepatic encephalopathy. The article concludes with a discussion regarding the modulation of lymphangiogenesis as a potential therapeutic strategy for liver diseases.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.